全文获取类型
收费全文 | 485篇 |
免费 | 30篇 |
国内免费 | 14篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 31篇 |
基础医学 | 39篇 |
口腔科学 | 9篇 |
临床医学 | 33篇 |
内科学 | 95篇 |
皮肤病学 | 6篇 |
神经病学 | 6篇 |
特种医学 | 126篇 |
外科学 | 26篇 |
综合类 | 8篇 |
预防医学 | 9篇 |
眼科学 | 2篇 |
药学 | 31篇 |
肿瘤学 | 93篇 |
出版年
2023年 | 1篇 |
2021年 | 5篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 7篇 |
2014年 | 6篇 |
2013年 | 7篇 |
2012年 | 4篇 |
2011年 | 7篇 |
2010年 | 5篇 |
2009年 | 17篇 |
2008年 | 8篇 |
2007年 | 13篇 |
2006年 | 10篇 |
2005年 | 10篇 |
2004年 | 10篇 |
2003年 | 8篇 |
2002年 | 4篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 11篇 |
1998年 | 19篇 |
1997年 | 26篇 |
1996年 | 24篇 |
1995年 | 16篇 |
1994年 | 18篇 |
1993年 | 12篇 |
1992年 | 18篇 |
1991年 | 12篇 |
1990年 | 11篇 |
1989年 | 18篇 |
1988年 | 17篇 |
1987年 | 20篇 |
1986年 | 16篇 |
1985年 | 20篇 |
1984年 | 16篇 |
1983年 | 21篇 |
1982年 | 21篇 |
1981年 | 19篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1978年 | 10篇 |
1977年 | 12篇 |
1976年 | 7篇 |
1975年 | 3篇 |
1972年 | 1篇 |
1968年 | 1篇 |
1967年 | 1篇 |
排序方式: 共有529条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Elizabeth Rosyold Russell Schilder Judy Walczak S. M. DiFino P. J. Flynn T. K. Banerjee W. J. Heim Paul E. Engstrom Robert F. Ozols Peter J. O'Dwyer 《Cancer chemotherapy and pharmacology》1992,29(4):305-308
Summary Phosphonacetyl-l-aspartate (PALA), an inhibitor of aspartate transcarbamylase that depletes uridine nucleotide pools, selectively potentiates the antitumor activity of 5-fluorouracil (5-FU) in preclinical models. Due to the promising results we obtained using PALA/5-FU in colorectal cancer, we performed a phase II trial in patients presenting with advanced pancreatic cancer. PALA was given intravenously at 250 mg/m2 on day 1, followed 24 h later by 2,600 mg/m2 5-FU given by 24-h infusion. Treatments were repeated weekly. A total of 41 patients who had not previously undergone chemotherapy were entered in the trial; of these, 35 were evaluable for response. Toxicity was generally mild to moderate; neurotoxicity (13/35) and diarrhea (8/35) predominated. Among the 35 patients, 1 achieved a complete response and 4, a partial remission, for an overall response rate of 14%. The median survival was 5.1 months. Pretreatment with PALA alone was not sufficient to enhance the activity of 5-FU in pancreatic cancer.Supported in part by grant CA 06927 from the National Cancer Institute 相似文献
5.
Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results 总被引:3,自引:0,他引:3
Mattrey RF; Strich G; Shelton RE; Gosink BB; Leopold GR; Lee T; Forsythe J 《Radiology》1987,163(2):339-343
In animals, perfluorochemicals (PFCs) are effective ultrasound (US) contrast agents that produce hepatic, splenic, and tumor enhancement. The use of Fluosol-DA 20%, an emulsion of perfluorodecalin and perfluorotripropylamine, was studied in nine non-critically ill patients with cancer who had liver lesions. US studies without Fluosol were compared with studies obtained 24, 48, and 72 hours after Fluosol infusion. Vital signs and extensive laboratory analyses are performed before and after Fluosol infusion. Liver metastases from colonic, pancreatic, and gastric carcinoma exhibited rim or diffuse enhancement after a Fluosol dose of 1.6 g/kg or greater. Fluosol produced echogenic enhancement of the liver and spleen relative to kidney at a dose of 2.4 g/kg, allowing the detection of nonenhancing lesions. In addition, Fluosol at a dose of 1.6 g/kg or greater allowed detection of lesions not seen before contrast medium was administered in three of the seven patients studied. There was a mild increase in the level of serum glutamic oxaloacetic transaminase in two patients, one given 2.4 and the other 3.2 g/kg of Fluosol. Mild and transient allergic reactions without change in vital signs were experienced by two patients. 相似文献
6.
Karen G. Louie Thomas C. Hamilton Robert H. Shoemaker Robert C. Young Robert F. Ozols 《Investigational new drugs》1992,10(2):73-78
Summary Five compounds which were identified as potential new anticancer drugs inin vitro screening with the human tumor colony forming assay were selected for further evaluation usingin vitro andin vivo models of human ovarian cancer. Three of five compounds were found to inhibitin vitro colony formation of ovarian cancer cell lines derived from both untreated and combination chemotherapy refractory patients. One compound was also found to prolong survival in a human ovarian carcinoma xenograft model system. This compound, chloroquinoxaline sulfonamide, was selected for development and has shown preliminary indication of activity in phase I clinical testing. 相似文献
7.
8.
9.
Dohle GR; Ramos L; Pieters MH; Braat DD; Weber RF 《Human reproduction (Oxford, England)》1998,13(3):620-623
Male genital tract obstructions may result from infections, previous
inguinal and scrotal surgery (vasectomy) and congenital bilateral absence
of the vas deferens (CBAVD). Microsurgery can sometimes be successful in
treating the obstruction. In other cases and in cases of failed surgical
intervention, the patient can be treated by microsurgical or percutaneous
epididymal sperm aspiration (MESA, PESA) or testicular sperm extraction
(TESE) and intracytoplasmic sperm injection (ICSI). We present the results
of 39 ICSI procedures for obstructive azoospermia in 24 couples. The
aetiology of the obstruction was failed microsurgery in 11 patients, CBAVD
in nine and genital infections in four. Sperm retrieval was accomplished
via MESA in four cases, PESA in 18 cases and via TESE in 11 cases. TESE was
only applied when PESA failed to produce enough spermatozoa for
simultaneous ICSI. In six patients, the ICSI procedure was performed with
cryopreserved spermatozoa after an initial PESA procedure. Fertilization
occurred in 47% of the metaphase II oocytes; embryo transfer was performed
in 92% of procedures and resulted in a clinical pregnancy in 13/39
procedures. Ongoing pregnancy was achieved in 10/39 procedures. One
pregnancy was terminated early after prenatal investigation showed a
cytogenetic abnormality (47,XX+18, Edwards syndrome). The other nine
pregnancies resulted in the live birth of 10 children, without any
congenital abnormalities. Epididymal and testicular retrieved spermatozoa
were successfully used for ICSI to treat obstructive azoospermia, and
resulted in an ongoing pregnancy in 10 of 24 couples (41.6%) after 39 ICSI
procedures, a success rate of 25.6% per treatment cycle and of 27.7% per
embryo transfer.
相似文献
10.